Methyl 5-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]pentanoate | 1012058-03-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: Methyl 5-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]pentanoate
• CAS: 1012058-03-5
• 化学式: C₂₁H₂₁ClFN₃O₃
• 分子量: 417.867
• InChiKey: MHWSHYPKUFTTQR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  29
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  73.3
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  Methyl 5-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]pentanoate 在 羟胺 、 溶剂黄146 作用下， 以 甲醇 为溶剂， 反应 0.5h， 以83%的产率得到5-(4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl)-N-hydroxypentanamide
  参考文献：
  名称：

  [EN] MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS
  [FR] PETITES MOLÉCULES MULTIFONCTIONNELLES SERVANT D'AGENTS ANTI-PROLIFÉRATIFS

  摘要：

  公开号：

  WO2008033747A3
• 作为产物：
  描述：

  methyl 5-(4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl)pent-4-ynoate 在 palladium 10% on activated carbon 氢气 作用下， 以 甲醇 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 16.0h， 以94%的产率得到Methyl 5-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]pentanoate
  参考文献：
  名称：

  [EN] MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS
  [FR] PETITES MOLÉCULES MULTIFONCTIONNELLES SERVANT D'AGENTS ANTI-PROLIFÉRATIFS

  摘要：

  公开号：

  WO2008033747A3

文献信息

• TARTRATE SALTS OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY
  申请人：Cai Xiong

  公开号：US20090076022A1

  公开（公告）日：2009-03-19

  The present invention relates to tartrate salts of quinazoline containing zinc-binding moiety based derivatives that are inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR-TK related diseases and disorders such as cancer. The tartrate salts may further act as HDAC inhibitors.

  本发明涉及含有锌结合基团的喹唑啉酸盐衍生物，这些衍生物是表皮生长因子受体酪氨酸激酶（EGFR-TK）的抑制剂，以及它们在治疗EGFR-TK相关疾病和疾病如癌症中的用途。这些酒石酸盐还可能作为HDAC抑制剂。
• FORMULATION OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY
  申请人：Cai Xiong

  公开号：US20090111772A1

  公开（公告）日：2009-04-30

  The present invention relates to a composition comprising an inclusion complex of a cyclodextrin and quinazoline containing zinc-binding moiety based derivatives. The cyclodextrin is preferable a β-cyclodextrin or a derivative thereof. The quinazolines have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR-TK related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.

  本发明涉及一种包含环糊精和喹唑啉含锌结合基团衍生物的包含复合物的组合物。环糊精最好是β-环糊精或其衍生物。喹唑啉具有增强和意想不到的性质，作为表皮生长因子受体酪氨酸激酶（EGFR-TK）的抑制剂，以及它们在治疗EGFR-TK相关疾病和疾病如癌症中的用途。所述衍生物还可以作为HDAC抑制剂。
• Multi-Functional Small Molecules as Anti-Proliferative Agents
  申请人：Cai Xiong

  公开号：US20080221132A1

  公开（公告）日：2008-09-11

  The present invention relates to the compositions, methods, and applications of a novel approach to selective inhibition of several cellular or molecular targets with a single small molecule. More specifically, the present invention relates to multi-functional small molecules wherein one functionality is capable of inhibiting histone deacetylases (HDAC) and the other functionality is capable of inhibiting a different cellular or molecular pathway involved in aberrant cell proliferation, differentiation or survival.

  本发明涉及一种新型选择性抑制多种细胞或分子靶点的组合物、方法和应用。更具体地说，本发明涉及多功能小分子，其中一种功能能够抑制组蛋白去乙酰化酶（HDAC），另一种功能能够抑制与异常细胞增殖、分化或存活有关的不同细胞或分子途径。
• QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY
  申请人：Qian Changgeng

  公开号：US20080139590A1

  公开（公告）日：2008-06-12

  The present invention relates to quinazoline containing zinc-binding moiety based derivatives that have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR-TK related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.

  本发明涉及含有锌结合基团的喹唑啉衍生物，其具有增强和意外的性质，作为表皮生长因子受体酪氨酸激酶（EGFR-TK）抑制剂，并用于治疗EGFR-TK相关的疾病和疾病，如癌症。所述衍生物还可以作为HDAC抑制剂。
• US7547781B2
  申请人：——

  公开号：US7547781B2

  公开（公告）日：2009-06-16